Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3403)	4/11/2001 9:25:15 AM
From: Jibacoa	Respond to of 52153

LJPC: No PM trades.<g> SAN DIEGO, April 11 /PRNewswire/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC - news) announces the publication of three papers on the clinical development of its lupus drug candidate, LJP 394, in Lupus, Expert Opinion of Investigational Drugs, and The Journal of Rheumatology. The Company is currently conducting a Phase III trial designed to confirm the ability of LJP 394 to treat lupus kidney disease. The first publication, authored by Vibeke Strand, M.D., Biopharmaceutical Consultant and Clinical Professor (VCS), Division of Immunology, Stanford University School of Medicine, includes a review of recent data on LJP 394. The paper, entitled ``Monoclonal antibodies and other biologic therapies,'' is included in a special issue of Lupus (volume 10, no. 3, 216-221) published for the recently held 6th International Lupus Conference. Concerning LJP 394 treatment, Dr. Strand stated that ``significant benefit was evident in patients with the greatest impairment of renal function pre-treatment.'' In a second publication, Daniel Wallace, M.D., Clinical Professor of Medicine, Cedars-Sinai/University of California Los Angeles, summarizes Phase I, II, and II/III clinical trial results for LJP 394. In the article, Dr. Wallace said, ``LJP 394 represents a unique approach to patients with serious lupus. It appears to be effective and non-toxic.'' He added, ``Definitive trials of LJP 394 for serious lupus are in progress.'' The article, published in Expert Opinion of Investigational Drugs, volume 10, no. 1, pp 111-117, is entitled ``Clinical and pharmacological experience with LJP 394.'' A third article, authored by Richard A. Furie M.D., Associate Professor of Clinical Medicine at the NYU School of Medicine, discusses the previously reported results of a six-month multicenter, placebo-controlled Phase II dose-ranging study in 58 patients. The article, entitled ``Treatment of systemic lupus erythematosus with LJP 394,'' was published in The Journal of Rheumatology, volume 28, no. 2, pp 257-265. Dr. Furie concluded, ``The clinical trial, in which a large number of patients were treated with LJP 394, expanded the safety profile of LJP 394 and demonstrated its capacity to reduce dsDNA antibodies.'' Chart: siliconinvestor.com siliconinvestor.com Bernard